What is the new oral corona treatment 'PF-07321332' developed by Pfizer?
by
Pfizer, a pharmaceutical company that develops the new coronavirus vaccine, has begun clinical trials of a new coronavirus infection treatment called 'PF-07321332'. Phase I clinical trials are scheduled to end on May 25, 2021, and if further clinical trials proceed smoothly, they may be brought to market by the end of the year.
Revealed: How a single pill home cure for Covid could be available this year
https://www.telegraph.co.uk/global-health/science-and-disease/revealed-home-cure-covid-could-available-year/
Pfizer's at-home pill to'cure' COVID-19 might be available by the end of the year | Daily Mail Online
https://www.dailymail.co.uk/health/article-9513319/Pfizers-home-pill-cure-COVID-19-available-end-year.html
PF-07321332, developed by Pfizer, is a type of drug called a 'protease inhibitor.' The new coronavirus causes infected cells to make the necessary proteins to multiply in the infected person's body. Proteases are enzymes that properly cleave and complete proteins made by cells. PF-07321332 works to prevent the growth of the new coronavirus by inhibiting the action of this protease.
Unlike vaccines that obtain immunity by incorporating genes that express proteins in advance, PF-07321332 is a therapeutic drug that suppresses the growth of the new coronavirus in the body. Therefore, PF-07321332 will be prescribed when the initial symptoms of the new coronavirus infection (COVID-19) are observed.
In addition, PF-07321332 is an orally administered tablet, and it is a major feature of PF-07321332 that it is easy to keep at home.
In clinical trials, PF-07321332 is prescribed in combination with the
According to the British general newspaper Telegraph, ongoing clinical trials will be conducted in three phases, for a total of 145 days. The first phase, the Phase I clinical trial, will be conducted in 60 subjects between the ages of 18 and 60 and will be completed by the end of May. If all goes well, all clinical trials will be completed in mid-July 2021 and may be prescribed in hospitals in the fall of 2021.
'Pfizer needs not only to manufacture effective drugs, but also to end development while the new coronavirus remains a public health threat,' Telegraph said.
When Daily Mail, an American news media, asked the National Institutes of Health and the Ministry of Health and Welfare for comments on PF-07321332, there was no response. A Pfizer spokeswoman also refused to answer questions such as 'whether the U.S. government is funding clinical trials for PF-07321332' and 'whether the U.S. government ordered PF-07321332.' Did.
Related Posts:
in Science, Posted by log1i_yk